https://www.cdc.gov/vaccines/programs/iis/COVID-19-related-codes.

html

,,•:,••,~ Centers for Disease

fl,,~_A_control and Prevention

COVID-19 Vaccine Related Codes

COVID-19 Vaccine Codes

Preview Posting of COVID-19 Vaccine Codes and Crosswalk for Currently

Authorized Vaccines and Anticipation of Potential Vaccine Availability
under Emergency Use Authorization (EUA)
Note: Codes will become effective only upon EVA issuance or BlA licensure of COVID-19 vaccine(s) by the Food and Drug
Administration (FDA)

The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials
for candidate vaccines progress. Additional vaccines or codes will be added to this list as they enter late-stage clinical trials or
prepare applications for FDA authorization.

The following downloadable table provides a summary of the currently authorized vaccine codes and a preview of the vaccine
codes that will be activated if the FDA authorizes use and ACI P votes to recommend the candidate vaccines.

To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine
codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and
users that require these codes to prepare in advance.

The codes for these vaccines are also included in the vaccine code set files unless otherwise noted in the table. Additional
code details and fields values are included in the vaccine code sets.

American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA
web site. The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets. You can
access further information regarding the COVI D-19 CPT codes, as well as the associated coding guidance, using the following
link:

https://www.ama-assn.org/practice-ma nagement/cpt/ covid-19-cpt-vacci ne-a nd-i mm u n ization-codes ~

Download the Preview Table for US vaccine administration only Excel Version Ltl

COVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved
Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-
EUA) as of 02/08/2022. Codes will become effective for US vaccine administrations only upon EUA issuance and/or BLA
approval of COVI D-19 vaccine(s) by the FDA. All CVX codes are associated to the new Vaccine Group "COVID-19." CPT Codes
shown are product codes. CPT administrative codes for doses are available on the AMA website. CPT product codes are added
as the AMA approves and makes them available.

FDA Unit of Unit of

Authorization Sale Sale Use
(BLA, EUA, Proprietary Product NDC10 UoS NDC10 UoU CVX CVX Long CVXShort
Manufacturer Pre-EUA) Name Description (UOS) Package (UOU) Presentation Code Description Description
 FDA Unit of Unit of
Authorization Sale Sale Use
(BLA, EUA, Proprietary Product NDC10 UoS NDC10 UoU 0/X 0/XLong 0/XShort
Manufacturer Pre-EUA) Name Description (UOS) Package (UOU) Presentation Code Description Description

Janssen EUA- Janssen Sx10" 10 59676- CARTON, 59676- VIAL, MULTl- 212 SARS-COV-2 (COVID- COVID-19 vaccine,
Products, LP authorized COVID-19 viral 580-15 10 580-05 DOSE 19) vaccine, vector vector-nr, rS-Ad26,
(18+) Vaccine particles/0.S MULTI- non-replicating, PF, 0.5 mL
(BLUE CAP) ml for adult DOSE recombinant spike
18+ VIALS protein-Ad26,
preservative free,
0.5 ml

Moderna US, EUA- Moderna 100 mcg/0.5 80777- CARTON, 80777- VIAL, 5 ml, 207 SARS-COV-2 (COVID- COVID-19, mRNA,
Inc. authorized COVID-19 ml for adult 273-99 10 273-10 MULTI-DOSE 19) vaccine, mRNA, LNP-S, PF, 100 mcg
(18+) Vaccine 18+ MULTI- VIAL spike protein, LNP, or 50 mcg dose
(REDCAP) (existing DOSE preservative free,
product) VIALS 100 mcg or 50 mcg
ml dose
EACH

80777- CARTON, 80777- VIAL, 7 ml,

273-98 10 273-15 MULTI-DOSE
MULTI- VIAL
DOSE
VIAL 7
ml
EACH

Moderna US, EUA- Moderna 50 mcg/0.25 80777- CARTON, 80777- VIAL, 5 ml, 207 SARS-COV-2 (COVID- COVID-19, mRNA,
Inc. authorized COVID-19 ml for 273-99 10 273-10 MULTI-DOSE 19) vaccine, mRNA, LNP-S, PF, 100 mcg
(18+) Vaccine booster MULTI- VIAL spike protein, LNP, or 50 mcg dose
(REDCAP) adult 18+ DOSE preservative free,
(existing VIALS 100 mcg or 50 mcg
product), ml dose
drawn from EACH
same vial as
primary
series 80777- CARTON, 80777- VIAL, 7 ml,
273-98 10 273-15 MULTI-DOSE
MULTI- VIAL
DOSE
VIAL 7
ml
EACH

Pfizer-BioNTech EUA- Pfizer- 30 mcg/0.3 59267- CARTON, 59267- MULTI-DOSE 208 SARS-COV-2 (COVID- COVID-19, mRNA,
authorized BioNTech ml for 1000-2 195 1000-1 VIAL 19) vaccine, mRNA, LNP-S, PF, 30
for ages 12 COVID-19 primary MULTI- spike protein, LNP, mcg/0.3 ml dose
yrs+ Vaccine series, IC DOSE preservative free, 30
(PURPLE 3rd dose, VIALS mcg/0.3 ml dose
CAP) booster

(Original
product
formulation)
 FDA Unit of Unit of
Authorization Sale Sale Use
(BLA, EUA, Proprietary Product NDC10 UoS NDC10 UoU 0/X 0/XLong 0/XShort
Manufacturer Pre-EUA) Name Description (UOS) Package (UOU) Presentation Code Description Description

59267- CARTON,
1000-3 25
MULTI-
DOSE
VIALS

Pfizer-BioNTech EUA- Pfizer- 30 mcg/0.3 59267- CARTON, 59267- VIAL, 2.25 217 SARS-COV-2 (COVID- COVID-19, mRNA,
authorized BioNTech ml for 1025-3 25 1025-1 ml, MULTI- 19) vaccine, mRNA, LNP-S, PF, 30
for ages 12 COVID-19 primary MULTI- DOSE VIAL spike protein, LNP, mcg/0.3 ml dose
yrs+ Vaccine series, IC DOSE preservative free, 30
Note: BLA- (GRAY CAP) 3rd dose, VIALS mcg/0.3 ml dose
licensed for booster
(16+) (Tris-
sucrose
formulation)

59267- CARTON,
1025-4 10
MULTI-
DOSE
VIALS

Pfizer-BioNTech EUA- Pfizer- 10 mcg/0.2 59267- CARTON, 59267- VIAL, 2 ml, 218 SARS-COV-2 (COVID- COVID-19, mRNA,
authorized BioNTech ml for 1055-4 10 1055-1 MULTI-DOSE 19) vaccine, mRNA, LNP-S, PF, 10
for ages 5 yrs COVID-19 primary MULTI- VIAL spike protein, LNP, mcg/0.2 ml dose,
to< 12yrs Vaccine series, IC DOSE preservative free, 1O tris-sucrose
(ORANGE 3rd dose VIALS mcg/0.2 ml dose,
CAP) tris-sucrose
formulation
(Tris-
sucrose
formulation)
 FDA Unit of Unit of
Authorization Sale Sale Use
(BLA, EUA, Proprietary Product NDC10 UoS NDC10 UoU cvx CVXLong CVXShort
Manufacturer Pre-EUA) Name Description (UOS) Package (UOU) Presentation Code Description Description

Pfizer-BioNTech Pre-EUA for Pfizer- 3 mcg/0.2 59267- CARTON, 59267- VIAL, 2 mL, 219 SARS-COV-2 (COVID- COVID-19, mRNA,
ages 6 mo to BioNTech mL for 0078-4 10 0078-1 MULTI-DOSE 19) vaccine, mRNA, LNP-S, PF, 3 mcg/0.2
<5 yrs COVID-19 primary MULTI- VIAL spike protein, LNP, mL dose, tris-
Vaccine series DOSE preservative free, 3 sucrose
(MAROON VIALS mcg/0.2 mL dose,
CAP) tris-sucrose
formulation
(Tris-
sucrose
formulation)

AstraZeneca Pre-EUA AstraZeneca sx10 11 10 No active NDC codes for U.S. Market 210 SARS-COV-2 (COVID- COVID-19 vaccine,
Pharmaceuticals COVID-19 viral 19) vaccine, vector vector-nr, rS-
LP Vaccine particles/0.5 non-replicating, ChAdOx1, PF, 0.5 mL
mL, adult recombinant spike
protein-ChAdOx1,
preservative free,
0.5 mL

Novavax, Inc. Pre-EUA Novavax 5 mcg/0.5 No active NDC codes for U.S. Market 211 SARS-COV-2 (COVID- COVID-19 vaccine,
COVID-19 mL, adult 19) vaccine, Subunit, Subunit, rS-
Vaccine recombinant spike nanoparticle+Matrix-
protein- M1 Adjuvant, PF, 0.5
nanoparticle+Matrix- mL
M1 Adjuvant,
preservative free,
0.SmL per dose
Unspecified US COVID-19 Vaccine CVX Code

0/XShort 0/X 0/XLong Vaccine

Description Code Description Note Status

SARS-COV-2 213 SARS-COV-2 Unspecified code for COVID-19 not to be used to record patient US administration. May be used to Inactive
(COVID-19) (COVID-19) record historic US administration if product is not known . 0/X code 500 should be used to record
vaccine, vaccine, Non-US vaccine where product is not known.
UNSPECIFIED UNSPECIFIED

The following vaccines and associated tradenames have been approved by the FDA under BLA License. They are listed
separately because while they may represent the same formulations as the EUA authorized and labeled products listed
above, the NDCs listed with the new BLA licensed tradenames in the FDA BLA approval or the FDA Structured Product Labels
(SPL) are not currently being produced by the manufacturers while EUA product is available.

FDA Unit of Unit of

Authorization Sale Sale Use
(BLA, EUA, Proprietary Product NDC10 NDC10 UoU
Manufacturer Pre-EUA) Name Description (UOS) UoS Package (UOU) Presentation

Pfizer- BLA-licensed COMIRNATY 30 mcg/0.3 0069- CARTON, 0069- VIAL, 2 ml,COMINARTY products are not orderable at this
BioNTech for ages 16+ ml for 1000- 195 MULTI- 1000- MULTI-DOSE time. NDCs are listed per FDA Structured Product
adult 16+ 02 DOSE VIALS 01 VIAL Label (SPL) document for the BLA licensed
(original product. These codes are not included in CDC
formula) Vaccine Code Set files at this time. Pfizer has
provided the following statement regarding the
COMINARTY branded NDCs and labels:
"Pfizer received FDA BLA license on 8/23/2021 for
its COVID-19 vaccine for use in individuals 16 and
00069- CARTON, 25 older (COMIRNATY). At that time, the FDA
1000- MULTI-DOSE published a BLA package insert that included the
03 VIALS
approved new COVID-19 vaccine tradename
COMIRNATY and listed 2 new NDCs (0069-1000-
03, 0069-1000-02) and images of labels with the
new tradename.

Pfizer subsequently received approval to amend

Pfizer- BLA-licensed COMIRNATY 30 mcg/0.3 0069- CARTON, 10 0069- VIAL, 2 ml, its FDA BLA License on December 16, 2021 to
BioNTech for ages 16+ ml for 2025- MULTI-DOSE 2025- MULTI-DOSE include its tris-sucrose formulation COVID-19
adult 16+ 10 VIALS 01 VIAL vaccine for use in individuals 16 and older
(Same as (COMIRNATY). At that time, the FDA published a
EUA tris BLA package insert that included the approved
sucrose new COVI D-19 vaccine tradename COM IRNATY
formula) and listed 3 new NDCs (0069-2025-10, 0069-
2025-25, 0069-2025-01) and images of labels with
the new tradename.

0069- CARTON, 25
2025- MULTI-DOSE At present, Pfizer does not plan to produce any
25 VIALS product with these new NDCs and labels over the
next few months while EUA authorized product is
still available and being made available for U.S.
distribution. As such, the CDC, AMA. and drug
compendia may not publish these new codes
until Pfizer has determined when the product will
be produced with the BLA labels."

Moderna US, BLA-licensed SPIKEVAX 0.5 ml 80777- CARTON, 10 NA VIAL, 5.5 ml, SPIKEVAX products are not orderable at this time.
Inc. for ages 18+ dose 100-99 MULTI-DOSE MULTI-DOSE NDCs are listed per FDA Structured Product Label
(same as VIALS, EACH VIAL (SPL) document for the BLA licensed product.
original VIAL These codes are not included in CDC Vaccine
EUA CONTAINING Code Set files at this time. Moderna has
formula) 5.5 ml provided the following statement regarding the
SPIKEVAX branded NDCs and labels:
"Moderna received FDA BLA license on January
31, 2022, for its COVID-19 vaccine SPIKEVAX
(COVID-19 Vaccine, mRNA) for use in individuals
18 and older. At that time, the FDA published a
 FDA Unit of Unit of
Authorization Sale Sale Use
(BLA, EUA, Proprietary Product NDC10 NDC10 UoU
Manufacturer Pre-EUA) Name Description (UOS) UoS Package (UOU) Presentation
BLA package insert that included the new
approved trade name SPIKEVAX and listed 2 new
NDCs (80777-100-99, 80777-100-98).

At present, Moderna does not plan to produce

80777- CARTON, 10 NA VIAL, 7.5 ml, any product with these new NDCs and labels
100-98 MULTI-DOSE MULTI-DOSE over the next few months while EUA authorized
VIALS, EACH VIAL Moderna COVID-19 Vaccine product is still
VIAL available and being made available for U.S.
CONTAINING distribution. As such, the CDC, AMA, and drug
7.5 ml compendia may delay publishing these new
codes until Moderna has determined when the
product will be produced with the BLA labels."

Download the Preview Table for Non-US vaccine administration only Excel Version lti

Preview Posting of COVID-19 Vaccine Codes and Crosswalks to be used for Non-US vaccine administration. All COVID-19
related CVX codes are associated to the Vaccine Group "COVID-19". Data as of 11/15/2021. CVX and MVX codes are identified
for vaccines that have received emergency authorization from the World Health Organization (WHO), US Food and Drug
Administration (FDA) or both. CVX codes have also been added without associated MVX for vaccines that are manufactured
and administered outside the US but which have not been authorized by the WHO. The list of vaccines not authorized by the
WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC
monitors WHO published information.

cvx CVX MVX MVX Product

Code CVX Long Description CVX Short Description CVX Note Status Code Manufacturer Tradename(s)

207 SARS-COV-2 (COVID-19) COVID-19, mRNA, LNP- EUA 12/18/2020, 2-dose vaccine. Used to record Active MOD Moderna US, Moderna
vaccine, mRNA, spike S, PF, 100 mcg or 50 Moderna vaccines administered in the US and Inc. COVID-19
protein, LNP, preservative mcg dose in non-US locations (includes tradename Vaccine (non-
free, 100 mcg or 50 mcg Spikevax) us Spikevax)
dose

208 SARS-COV-2 (COVID-19) COVID-19, mRNA, LNP- EUA 12/11/2020, 2-dose vaccine. Used to record Active PFR Pfizer, Inc Pfizer-
vaccine, mRNA, spike S, PF, 30 mcg/0.3 ml Pfizer vaccines administered in the US and in BioNTech
protein, LNP, preservative dose non-US locations (includes tradename COVID-19
free, 30 mcg/0.3mL dose Comirnaty) Vaccine (US-
EUA),
COMIRNA1Y
(US-BLA),
COMIRNA1Y
(Non-US)

210 SARS-COV-2 (COVID-19) COVID-19 vaccine, Potential EUA, 2-dose vaccine. AstraZeneca Non- ASZ AstraZeneca AstraZeneca
vaccine, vector non- vector-nr, rS-ChAdOx1, vaccine is authorized by the WHO and US COVID-19
replicating, recombinant PF, 0.5 ml recognized towards immunity in the US. Non-US Vaccine (Non-
spike protein-ChAdOx1, WHO authorized tradenames/identifiers include US
preservative free, 0.5 ml VAXZEVRIA, AZD1222, ChAdOx1 nCoV-19, tradenames
COVISHIELD include
VAXZEVRIA,
COVISHIELD)

212 SARS-COV-2(COVID-19) COVID-19 vaccine, EUA 02/27/2021, 1-dose vaccine. Used to record Active JSN Janssen Janssen (J&J)
vaccine, vector non- vector-nr, rS-Ad26, PF, Janssen/J&J vaccines administered in the US and COVID-19
replicating, recombinant 0.5 ml in non-US locations Vaccine
spike protein-Ad26,
preservative free, 0.5 ml

510 SARS-COV-2 COVID-19 COVID-19 IV Non-US WHO authorized pandemic vaccine. Recognized Non- SPH Sinopharm- Sinopharm
Inactivated Virus Non-US Vaccine (BIBP, towards immunity in US US Biotech (BIBP) COVID-
Vaccine Product (BIBP, Sinopharm) 19 Vaccine
Sinopharm)
0/X 0/X MVX MVX Product
Code 0/X Long Description 0/X Short Description 0/XNote Status Code Manufacturer Tradename(s)

511 SARS-COV-2 COVID-19 COVID-19 IV Non-US WHO authorized pandemic vaccine. Recognized Non- SNV Sinovac Coronavac
Inactivated Virus Non-US Vaccine (CoronaVac, towards immunity in US us (Sinovac)
Vaccine Product Sinovac) COVID-19
(CoronaVac, Sinovac) Vaccine

500 SARS-COV-2 COVID-19 COVID-19 Non-US Pandemic Non-US Covid Administration - Non-
Non-US Vaccine, Specific Vaccine, Product specific CVX or product unknown us
Product Unknown Unknown

501 SARS-COV-2 COVID-19 COVID-19 IV Non-US Pandemic Non-US Vaccine not Authorized by Non-
Inactivated Virus Non-US Vaccine (QAZCOVID-IN) WHO - not counted toward immunity in US us
Vaccine Product
(QAZCOVID-IN)

502 SARS-COV-2 COVID-19 COVID-19 IV Non-US Pandemic Non-US Vaccine Authorized by WHO Non- BBi Bharat COVAXIN
Inactivated Virus Non-US Vaccine (COVAXIN) 11-3-2021, recognized toward immunity in US, us Biotech (Bharat)
Vaccine Product (COVAXIN) https://extranet.who.int/pqweb/vaccines/who- International COVID-19
recommendation-bharat-biotech-international- Limited Vaccine
ltd-covid-19-vaccine-whole-virion

503 SARS-COV-2 COVID-19 Live COVID-19 LAV Non-US Pandemic Non-US Vaccine not Authorized by Non-
Attenuated Virus Non-US Vaccine (COVIVAC) WHO - not counted toward immunity in US us
Vaccine Product (COVIVAC)

504 SARS-COV-2 COVID-19 Viral COVID-19 Wnr Non-US Pandemic Non-US Vaccine not Authorized by Non-
Vector Non-replicating Vaccine (Sputnik Light) WHO - not counted toward immunity in US us
Non-US Vaccine Product
(Sputnik Light)

505 SARS-COV-2 COVID-19 Viral COVID-19 Wnr Non-US Pandemic Non-US Vaccine not Authorized by Non-
Vector Non-replicating Vaccine (Sputnik V) WHO - not counted toward immunity in US us
Non-US Vaccine Product
(Sputnik V)

506 SARS-COV-2 COVID-19 Viral COVID-19 Wnr Non-US Pandemic Non-US Vaccine not Authorized by Non-
Vector Non-replicating Vaccine (Cansino WHO - not counted toward immunity in US us
Non-US Vaccine Product Biological lnc./Beijing
(Cansino Biological Institute of
lnc./Beijing Institute of Biotechnology)
Biotechnology)

507 SARS-COV-2 COVID-19 COVID-19 PS Non-US Pandemic Non-US Vaccine not Authorized by Non-
Protein Subunit Non-US Vaccine (Anhui Zhifei WHO - not counted toward immunity in US us
Vaccine Product (Anhui Longcom
Zhifei Longcom Biopharmaceutical +
Biopharmaceutical + Institute of
Institute of Microbiology, Microbiology, Chinese
Chinese Academy of Academy of Sciences)
Sciences)

508 SARS-COV-2 COVID-19 COVID-19 PS Non-US Pandemic Non-US Vaccine not Authorized by Non-
Protein Subunit Non-US Vaccine Uiangsu WHO - not counted toward immunity in US us
Vaccine Product Uiangsu Province Centers for
Province Centers for Disease Control and
Disease Control and Prevention)
Prevention)

509 SARS-COV-2 COVID-19 COVID-19 PS Non-US Pandemic Non-US Vaccine not Authorized by Non-
Protein Subunit Non-US Vaccine WHO - not counted toward immunity in US us
Vaccine Product (EpiVacCorona)
(EpiVacCorona)

COVID-19 Emergency Use Authorization Recipient and

Caregiver Fact Sheets
Preview Posting of Codes for Emergency Use Authorization (EUA) Fact
Sheets for Recipients and Caregivers
Vaccine information statements (VISs), used only for licensed vaccines, will not be available for COVID-19 vaccines while they
are under Emergency Use Authorization (EUA). For vaccines under an EUA, the FDA requires a vaccine-specific Fact Sheet for
Recipients and Caregivers be provided to vaccine recipients or their caregivers.

The COVID-19 vaccine-related codes are provided in anticipation of potential vaccine availability under an EUA. If a vaccine is
not authorized, the code will be retired.

The FDA issued Emergency Use Authorization for the Moderna COVID-19 vaccine on Friday December 18, 2020.
Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact
Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-
vaccine ~

The FDA issued Emergency Use Authorization for the Pfizer BioNTech COVI D-19 vaccine on Friday December 11, 2020.
Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact
Sheets is now available on the following FDA web site link:

https://www.fda.govI emergency-preparedness-and-response/coronavi rus-d isease-2019-covid-19/pfizer-biontech-covid-

19-vacci ne ~

The FDA issued Emergency Use Authorization for the Janssen Uohnson &Johnson) COVID-19 vaccine on Saturday
February 27, 2021. Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient
and Caregiver Fact Sheets is now available on the following FDA web site link:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-
vaccine ~

The following downloadable VIS code files will include the new EUA Fact Sheet for Recipients records:

• Excel version of table 18

EUA
Recipient/Caregiver
CVX Fact Sheet Edition Edition
Code Description Document Barcode String Date Status HTML URL PDF URL

207 COVID-19 Moderna 253088698300034911210601 1/31/2022 Current https://www.cdc.gov/vaccines/covid- https://www.cdc.gov/vaccines/covid•

Vaccine EUA 19/eua/modernatx.html 19/eua/modernatx.pdf ■
Recipient-Caregiver
Fact Sheet

208, COVID-19 Pfizer 253088698300033211210501 1/3/2022 Current https://www.cdc.gov/vaccines/covid- https://www.cdc.gov/vaccines/covid·

217 BioNTech EUA 19/eua/pfizer.html 19/eua/pfizer.pdf ■
Recipient-Caregiver
Fact Sheet - 12
years and older

218 COVID-19 pfizer 253088698300042411211001 1/3/2022 Current https://www.cdc.gov/vaccines/covid- https://www.cdc.gov/vaccines/covid•

BioNTech EUA 19/eua/pfizer-children.html 19/eualpfizer-children.pdf ■
Recipient-Caregiver
Fact Sheet-
Pediatric 5 - 11
years

219 COVID-19 Pfizer 253088698300048611220101 3/1/2022 Current https://www.cdc.gov/vaccines/covid- https://www.cdc.gov/vaccines/covid-

BioNTech EUA 19/eua/pfizer-children-under-5- 19/eua/pfizer-children-under-5-
Recipient-Caregiver years.html years.pdf ■
Fact Sheet-
Pediatric <5 yrs
 EUA
Recipient/Caregiver
CVX Fact Sheet Edition Edition
Code Description Document Barcode String Date Status HTML URL PDF URL

212 COVID-19 Janssen 253088698300036311210201 12/14/2021 Current https://www.cdc.gov/vaccines/covid- https://www.cdc.gov/vaccines/covid•

Vaccine EUA 19/eua/janssen.html 19/eua/janssen.pdf ■
Recipient-Caregiver
Fact Sheet

*Edition Date represents the date of update printed on the actual fact sheet document published by the FDA. It may not be
the same as the EUA authorization date or the date embedded in the Document Barcode String.

Page last reviewed: February 9, 2022